Biodesix/Aveo: A Harbinger Of Deals To Come

Aveo Pharmaceuticals and Biodesix have entered into a worldwide agreement to develop and commercialize Aveo’s ficlatuzumab, an antibody that inhibits hepatocyte growth factor, using Biodesix’s serum-based companion diagnostic VeriStrat, which guides treatment decisions for patients with advanced non-small cell lung cancer.